Moomoo AI 已提取核心信息
On February 23, 2024, Pfizer Inc. (Pfizer) and its wholly-owned subsidiary Pfizer Investment Enterprises Pte. Ltd. (Pfizer Singapore) filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the issuance of various securities, including debt securities, common stock, preferred stock, warrants, depositary shares, purchase contracts, and purchase units. The registration statement allows for the sale of these securities from time to time in one or more offerings. The securities may be offered at fixed prices, prevailing market prices, or negotiated prices, and may be sold through underwriters, dealers, agents, directly to purchasers, or through a combination of these methods. The registration statement also includes provisions for the indemnification of directors and officers, and outlines the potential anti-takeover effects of Pfizer's corporate governance documents and Delaware law. The specific terms of any offering, including the names of any underwriters and the compensation provided to them, will be detailed in future prospectus supplements filed with the SEC.
On February 23, 2024, Pfizer Inc. (Pfizer) and its wholly-owned subsidiary Pfizer Investment Enterprises Pte. Ltd. (Pfizer Singapore) filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the issuance of various securities, including debt securities, common stock, preferred stock, warrants, depositary shares, purchase contracts, and purchase units. The registration statement allows for the sale of these securities from time to time in one or more offerings. The securities may be offered at fixed prices, prevailing market prices, or negotiated prices, and may be sold through underwriters, dealers, agents, directly to purchasers, or through a combination of these methods. The registration statement also includes provisions for the indemnification of directors and officers, and outlines the potential anti-takeover effects of Pfizer's corporate governance documents and Delaware law. The specific terms of any offering, including the names of any underwriters and the compensation provided to them, will be detailed in future prospectus supplements filed with the SEC.
2024年2月23日，辉瑞公司（Pfizer）及其全资子公司辉瑞投资企业私人有限公司Ltd.（新加坡辉瑞）向美国证券交易委员会（SEC）提交了发行各种证券的注册声明，包括债务证券、普通股、优先股、认股权证、存托股票、购买合约和购买单位。注册声明允许不时通过一次或多次发行出售这些证券。证券可以按固定价格、现行市场价格或协议价格发行，可以通过承销商、交易商、代理商出售，直接出售给买方，也可以通过这些方法的组合出售。注册声明还包括对董事和高级管理人员进行赔偿的条款，并概述了辉瑞公司治理文件和特拉华州法律的潜在反收购影响。未来向美国证券交易委员会提交的招股说明书补充文件将详细说明任何发行的具体条款，包括任何承销商的姓名和向他们提供的补偿。
2024年2月23日，辉瑞公司（Pfizer）及其全资子公司辉瑞投资企业私人有限公司Ltd.（新加坡辉瑞）向美国证券交易委员会（SEC）提交了发行各种证券的注册声明，包括债务证券、普通股、优先股、认股权证、存托股票、购买合约和购买单位。注册声明允许不时通过一次或多次发行出售这些证券。证券可以按固定价格、现行市场价格或协议价格发行，可以通过承销商、交易商、代理商出售，直接出售给买方，也可以通过这些方法的组合出售。注册声明还包括对董事和高级管理人员进行赔偿的条款，并概述了辉瑞公司治理文件和特拉华州法律的潜在反收购影响。未来向美国证券交易委员会提交的招股说明书补充文件将详细说明任何发行的具体条款，包括任何承销商的姓名和向他们提供的补偿。
有用
没用